M.Pharm

NIPER Ahmedabad was initiated with three specializations Biotechnology, Natural Products and Pharmaceutics and over the period of time three more specialisations Pharmaceutical Analysis, Medicinal Chemistry and Pharmacology and Toxicology were added in 2010. Subsequently in 2011, to cater the needs of Medical device industry in India, another feather was added to the cap of NIPER Ahmedabad in the form of specialisation in Medical Devices.

Established on October 1, 1933 as University Department of Chemical Technology (popularly called UDCT) of the University of Bombay (now Mumbai), with the noble intention of advancing India's knowledge reserves in chemical science and technology, the Institute has grown to become a premier (deemed) university devoted to education, training, research and industrial collaboration in chemical engineering, chemical technology, applied chemistry, pharmacy, biotechnology and bio-processing.

Alagappa University was brought into existence by a Special Act of the Government of Tamil Nadu in May 1985 with the objective of fostering research, development and dissemination of knowledge in various branches of learning. Alagappa University is recognized by the University Grants Commission (UGC) of India. The University has 44 Departments, 9 Centres and 2 Constituent Colleges on its campus. 46 Affiliated Colleges located in the districts of Sivaganga and Ramanathapuram are part of the University.

Sentiss is committed to providing the best quality pharmaceutical products primarily in the Ophthalmic, ENT and Inhalation segments. Over the past 25 years, by exhibiting commitment and showcasing our winning culture, Sentiss has evolved tremendously and is recognized as the third best Ophthalmic Company (IMS 2015) in Russia. Sentiss’ footprint on the world map is a testimony to its quality philosophy and practice of product differentiation.

Multiple openings in Analytical and Formulation R&D for Ophthalmics and Injectables

Amneal Pharmaceuticals, Inc is an integrated specialty pharmaceutical company powered by a robust U.S. generics business and a growing branded business. Together, our team is working to build one of the most dynamic pharmaceutical companies in our rapidly changing industry.  Today’s healthcare environment requires a new approach and new ideas.

Post : Executive/Officer & Operator

Shilpa Medicare Limited started its operations as API manufacturer way back in 1987 at Raichur, Karnataka- India. The commercial production in the SML was started in November 1989. Today Shilpa Medicare Limited is a global brand in manufacturing and supplying of affordable API and Formulation globally in different regulated markets.

All India Institute of Medical Sciences (AIIMS), Kalyani, an Institute of National Importance is one of the new upcoming AIIMS and apex healthcare Institute under the Pradhan Mantri Swasthya Suraksha Yojana (PMSSY) has been established by the Ministry of Health and Family Welfare, Govt. of India, with the aim of correcting regional imbalance in quality tertiary level healthcare in the country, and attaining self-sufficiency in graduate, postgraduate and higher medical education and training.

Radicon is a specialty pharmaceutical company incorporated in the year 2007 by Late Mr. Rakesh Kumar Khaneja whose passion toward this fueled the company's growth. Radicon is engaged in manufacturing and marketing of quality finished dosage. Committed for serving the healthcare needs worldwide. We produce a comprehensive range of specialty products targeting different therapeutic segments for treatment of patients, customized to each market we are present in. We clearly understand our customer’s needs and use cutting edge technology to present innovative solutions.

Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer of small volume liquid parenteral products, to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets. We operate primarily under a business to business (B2B) model and have an excellent track record in the development, manufacturing and marketing of complex injectables.